Method for transdermal administration of gp iib/iiia antagonist
AssigneeHisamitsu Pharmaceutical Co., Inc.
InventorsKATSUMI IGA, YUKIHIRO MATSUMOTO
Life of this patent
Estimating the term…
Abstract
A method for transdermal administration of a GP IIb/IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density. The method insures excellent pharmacologic efficacy with a low risk for side effects in the prevention and therapy of (1) angina pectoris, (2) unstable angina and (3) ischemic complications and coronary arterial reocclusion or restenosis associated with PTCA or coronary thrombolysis.
Claims17
A method for transdermal administration of a GP IIb/IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density.
A method for transdermal administration of a GP IIb/IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density, followed by further series of electric current application(s) sufficient to maintain pharmacologically effective GP IIb/IIIa antagonist concentration in the serum.
A method for transdermal administration of a GP IIb/IIIa antagonist by iontophoresis, wherein the antagonist concentration in the serum is maintained at about 10 to 500 ng/ml, within 240 minutes from initial electric current application step.
Dependencies are inferred from the claim text.